Gilbert, J., Le Tourneau, C., Mehanna, H., Fayette, J., Goswami, T., Emeribe, U., . . . Siu, L. L. (2015). Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR. J Immunother Cancer.

Gilbert, Jill, Christophe Le Tourneau, Hisham Mehanna, Jerome Fayette, Trishna Goswami, Ugochi Emeribe, Anthony Jarkowski, Giovanni Melillo, und Lilian L. Siu. "Phase II, Randomized, Open-label Study of Durvalumab (MEDI4736) or Tremelimumab Monotherapy, or Durvalumab + Tremelimumab, in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): CONDOR." J Immunother Cancer 2015.

Gilbert, Jill, et al. "Phase II, Randomized, Open-label Study of Durvalumab (MEDI4736) or Tremelimumab Monotherapy, or Durvalumab + Tremelimumab, in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): CONDOR." J Immunother Cancer 2015.